By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand today said that its BioSeek subsidiary will screen Amylin Pharmaceuticals' library of compounds to discover peptides with a potential for treating inflammatory conditions.

Under a one-year contract, BioSeek will apply its BioMap predictive human disease models to screen Amylin's library. The new deal builds on earlier similar agreements between the two firms involving peptide screening and related drug discovery activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."